MediGene (ETR:MDG1) has been given a €12.50 ($14.88) price target by investment analysts at Independent Research in a research report issued on Wednesday. The brokerage currently has a “neutral” rating on the stock. Independent Research’s price objective suggests a potential upside of 6.47% from the stock’s previous close.

Other analysts have also recently issued reports about the stock. Baader Bank set a €19.00 ($22.62) target price on shares of MediGene and gave the stock a “buy” rating in a research note on Thursday, November 9th. Oddo Securities set a €12.00 ($14.29) price objective on shares of MediGene and gave the company a “buy” rating in a research note on Tuesday, August 8th.

MediGene (MDG1) traded down €0.28 ($0.33) during mid-day trading on Wednesday, reaching €11.74 ($13.98). 154,281 shares of the company were exchanged, compared to its average volume of 226,240. MediGene has a one year low of €8.40 ($10.00) and a one year high of €15.24 ($18.14).

WARNING: This article was reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at

About MediGene

Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.

Receive News & Ratings for MediGene AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene AG and related companies with's FREE daily email newsletter.